ClinicalTrials.gg
CompletedNCT02472418Updated May 22, 2018

Two Dose Levels of DFN-15 vs. Placebo in Patients With Migraine Headaches

A Phase 2 interventional study of DFN-15 Dose A (treatment A) and DFN-15 Dose B (treatment B) in Migraine, sponsored by Dr. Reddy's Laboratories Limited. Completed at 6 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-05-22.

Sponsored by Dr. Reddy's Laboratories Limited · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
63
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 696 studies in Migraine Disorders with a site in United States — 93 open to participants now, 115 under way, 27 of them phase 3. Migraine Disorders · United States.

Enrollment
337th of 609
63 · median 78
Started
2015
with 29 others
Phase 2
90 of 696
7 open now
Registered
270th of 696
by date

Among the 696 studies in Migraine Disorders with a site in United States, this one is the 337th largest by enrollment of the 609 interventional ones that give a count, is one of 30 that started in 2015, is one of 90 in phase 2, and was the 270th registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

93 of the 696 studies in Migraine Disorders with a site in United States are open now. Recruiting first, the newest first:

88 more — sign in →

All 93 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 696 studies in Migraine Disorders with a site in United States, or all of them as a file.
02

Study summary

Crossover study of DFN-15 dose A versus DFN-15 dose B versus Placebo in the treatment of migraine headaches.

03

Conditions studied

  • Migraine

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with a history of episodic migraine (as defined by International Classification of Headache Disorders [ICHD]-228) who experience an average of 2 to 6 migraine attacks a month for the past 12 months with no more than 14 headache days per month, and with at least 48 hours of headache-free time between migraine attacks;
  2. Patients with onset of migraine with or without aura before age 50;
  3. Patients who have migraine with or without aura, in which the aura cannot last longer than 60 minutes;
  4. Patients who report usual migraine pain of 2 (moderate) or 3 (severe) on headache pain severity scale.

Exclusion criteria

Exclusion Criteria:

  1. Patients with medication overuse headache (MOH) as defined by ICHD-228:

    • Opioids ≥ 10 days a month during the 90 days prior to screening
    • Combination medications (eg, Fiorinal® ≥ 10 days a month)
    • Nonsteroidal anti-inflammatory drugs (NSAIDs) or other simple medications > 14 days a month during the 90 days prior to screening
    • Triptans or ergots ≥ 10 days a month during the 90 days prior to screening
  2. Patients on chronic warfarin sodium;
  3. Patients taking monoamine oxidase-A (MAO-A) inhibitors;
  4. Patients on unstable dosages of chronic medications during the 3 months prior to and through screening, or who are not willing or able to maintain a stable pre-study dose throughout study participation;
  5. Patients with more than 6 migraine attacks a month and/or more than 14 headache days a month (based upon patient self-report);
  6. Patients with hemiplegic migraine or migraine with brain stem aura or other forms of neurologically complicated migraine;
  7. Patients with atypical aura;
  8. Patients with prolonged aura (more than 1 hour).
  9. Patients with a history of stroke or ;
  10. Patients with a history of migralepsy or a concurrent diagnosis of seizure disorder;
  11. Patients who cannot differentiate between a migraine headache and a tension-type or cluster headache or any other non-migraine headache;
  12. Patients with a history of more than 10 tension-type headaches per month;
  13. Patients with a history of cluster headache;
  14. Patients with a diagnosis of ICHD-2 "probable migraine";
  15. Patients with uncontrolled hypertension (screening blood pressure ≥ 140/90 mmHg despite appropriate pharmacotherapy);
  16. Patients with severe renal impairment (defined as serum creatinine > 1.9 mg/dL);
  17. Patients with serum total > 1.9 mg/dL;
  18. Patients with serum (AST), alanine aminotransferase (ALT), or alkaline phosphatase > 3 times the ;
  19. Patients with positive serology for (HIV), surface antigen, antibody.
  20. Patients with a history of alcohol or substance abuse (including marijuana and medical marijuana) within 1 year that would compromise data collection;
  21. Patients with a history of or current neurological or psychiatric impairment, or cognitive dysfunction that, in the opinion of the investigator, would compromise data collection;
  22. Patients with any other medical condition that, in the judgment of the investigator or medical monitor, would confound the objectives of the study (eg, cancer history [except basal cell carcinoma], systemic lupus erythematosus);
  23. Patients who have participated in a clinical trial involving any medication during the past 30 days or 5 half-lives of the study medication, whichever is longer
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
63 participants (actual)

Study arms

  • Experimental
    DFN-15 120 mg (treatment A)

    DFN-15 120 mg (treatment A)

    Drug: DFN-15 Dose A (treatment A)

  • Experimental
    DFN-15 240 mg (treatment B)

    DFN-15 240 mg (treatment B)

    Drug: DFN-15 Dose B (treatment B)

  • Placebo comparator
    Placebo (treatment C)

    Placebo (treatment C)

    Other: Placebo (treatment C)

Interventions

  • DrugDFN-15 Dose A (treatment A)

    DFN-15 Dose A administered

    Also known as: DFN-15 120 mg

  • DrugDFN-15 Dose B (treatment B)

    DFN-15 Dose B administered

    Also known as: DFN-15 240 mg

  • OtherPlacebo (treatment C)

    Placebo administered

    Also known as: Placebo (no active ingredient)

06

What researchers measure

Primary outcomes

  1. Pain Free, defined as a score of "0" on a numerical scale of "0" to "3"

    Percentage of subjects who are migraine headache free at 2 hours after taking study drug administration

    Time frame: 2 hour

07

Study locations

6 sites
  • Collaborative Neuroscience Network, LLC
    Long Beach, California 90806, United States
  • California Medical Clinic for Headache
    Santa Monica, California 90404, United States
  • MedVadis Research Corporation
    Watertown, Massachusetts 02472, United States
  • Michigan Head Pain & Neurological Institute
    Ann Arbor, Michigan 48104, United States
  • Clinvest/ A Division of Banyan Group, Inc.
    Springfield, Missouri 65807, United States
  • Albuquerque Clinical Trials, Inc.
    Albuquerque, New Mexico 87102, United States
08

References and documents

Publications

  • Munjal S, Bennett A. Efficacy and safety of DFN-15, an oral liquid formulation of celecoxib, in adults with migraine: a multicenter, randomized, placebo-controlled, double-blind, crossover study. Neuropsychiatr Dis Treat. 2017 Nov 7;13:2797-2802. doi: 10.2147/NDT.S151834. eCollection 2017. PubMed 29158678 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2015 to primary completion in Dec 2015, 5 months.

Of 43 industry-sponsored phase 2 interventional studies under Migraine Disorders, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's 5 months is below that.

Counting every sponsor, half of 73 studies reached it within 15 months; a quarter within 11 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2015
First posted
Jun 15, 2015
StartActual
Jun 5, 2015
Primary completionActual
Dec 1, 2015
CompletionActual
May 5, 2016
Results delay requested
May 15, 2018
Last update
May 22, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02472418
Responsible party
Sponsor
First posted
Jun 15, 2015
Start date
Jun 5, 2015
Primary completion
Dec 1, 2015
Completion
May 5, 2016
Last update
May 22, 2018
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion